Altimmune (NASDAQ:ALT) Now Covered by Leerink Partners

Stock analysts at Leerink Partners started coverage on shares of Altimmune (NASDAQ:ALT) in a research report issued on Monday, MarketBeat reports. The firm set an “outperform” rating and a $10.00 price target on the stock. Leerink Partners’ price target would indicate a potential upside of 236.13% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Friday, March 27th. Truist Financial started coverage on shares of Altimmune in a report on Wednesday, March 18th. They set a “buy” rating and a $12.00 price objective on the stock. Citizens Jmp dropped their price objective on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. Finally, B. Riley Financial reduced their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a report on Friday, March 6th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.71.

Altimmune Stock Up 10.2%

ALT stock traded up $0.28 during trading on Monday, reaching $2.98. 733,636 shares of the stock were exchanged, compared to its average volume of 4,210,808. The firm’s 50 day moving average is $2.96 and its 200 day moving average is $3.82. The firm has a market cap of $578.55 million, a P/E ratio of -3.22 and a beta of 0.21. The company has a current ratio of 29.56, a quick ratio of 29.56 and a debt-to-equity ratio of 0.12. Altimmune has a twelve month low of $2.56 and a twelve month high of $7.73.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. As a group, research analysts forecast that Altimmune will post -0.69 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALT. PVG Asset Management Corp bought a new stake in Altimmune in the 1st quarter worth about $204,000. Bank of America Corp DE lifted its position in shares of Altimmune by 48.6% during the 1st quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock worth $1,756,000 after buying an additional 186,420 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Altimmune by 101.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 35,650 shares of the company’s stock worth $110,000 after buying an additional 17,967 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Altimmune by 26.0% in the first quarter. The Manufacturers Life Insurance Company now owns 34,763 shares of the company’s stock valued at $107,000 after acquiring an additional 7,167 shares in the last quarter. Finally, Quantinno Capital Management LP bought a new position in shares of Altimmune in the first quarter valued at approximately $33,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.